If you are reading about SPRAVATO® because depression has been heavy for a long time, you may already feel tired from trying to understand one more treatment option. You may also be reading for someone you love, hoping to find language that feels clear without feeling cold.
This guide explains what SPRAVATO® (esketamine) nasal spray is, how supervised dosing works and what you can discuss with your clinician. We will use “esketamine” after this first mention so the reading feels easier. This article cannot replace personal medical advice and it should not be used to decide eligibility on your own.
If you are having urgent thoughts of self-harm or suicide, please treat that as an emergency. Your safety comes first. Contact your clinician, call emergency services in your area, go to an emergency department or ask someone you trust to stay with you while you get help.
Who This Overview Is For
You may have arrived here after months or years of trying to feel better. You may have heard about esketamine from a clinician, a friend or a family member who wants to help. However you found your way here, you deserve information that gives you steadiness instead of pressure.
This overview is for you if:
We will walk through what esketamine is, how it works at a high level, what the evidence suggests and why monitoring is built into the process. We will also talk through practical pieces that often weigh on people before treatment, including scheduling, transportation and insurance authorization.
This is not a self-screening tool. Your medical history, medications, blood pressure, substance use, pregnancy status and diagnosis all matter. A clinician who knows your full picture can help you understand whether esketamine belongs in your care plan.
A Few Terms That Make the Rest Easier
Medical language can make an already tender subject feel even more distant. Clear definitions can lower the noise and help you ask better questions.
Treatment-resistant depression is a phrase clinicians may use when depression has not improved enough after more than one well-delivered antidepressant trial. “Well-delivered” can include the right dose, enough time on the medication and a careful review of adherence and side effects.
Ketamine and esketamine are related, but they are not interchangeable. Ketamine has been used in medicine for decades. Esketamine is one form of ketamine that was developed into an FDA-approved product with specific rules for dosing and monitoring.
Intranasal means the medication is delivered through the nose, where it can be absorbed into the bloodstream. That route feels different from taking a daily pill at home and it changes the day-of treatment experience.
Glutamate and NMDA come up because esketamine acts on a brain signaling system that differs from many traditional antidepressants. You can think of them as part of the communication network that affects mood circuits, learning and stress responses.
Treatment-Resistant Depression in Plain Language
Treatment-resistant depression is more common than many people realize and it is not a personal failure. Depression can stay stuck for many reasons, including biology, chronic stress, trauma history, grief, isolation, medical illness, sleep disruption and medication tolerability.
When depression does not lift, clinicians often step back and look again at the whole picture. They may revisit the diagnosis, screen for bipolar features, review sleep and substance use, check thyroid or other medical contributors and confirm whether past medication trials had enough time and dose to work.
That re-checking can feel frustrating when you are exhausted, but it can also protect you. A careful review helps your team avoid treating only one piece of the problem while other drivers continue to pull on your mood, energy and daily functioning.
Ketamine vs. Esketamine and What “Intranasal” Means
Esketamine is related to ketamine and the FDA-approved form is delivered as a nasal spray in a clinic setting. The product rules shape how dosing is supervised and why observation is required.
When people say “intranasal,” they mean the medication is administered through the nasal passages. After that, the body absorbs the medication in a different way than it would absorb an oral medication. For you, that means treatment happens in a supervised visit rather than at home on your own.
What Esketamine Treatment Is and What It Is Not
Esketamine is a prescription medication used in specific situations and administered under clinical observation. Per FDA labeling, esketamine may be used together with an oral antidepressant or as a standalone treatment for treatment-resistant depression. For major depressive disorder with acute suicidal ideation or behavior, it is used together with an oral antidepressant.
Your clinician may describe esketamine as one option to consider when depression has not responded to other steps. That framing matters. Esketamine is not a quick fix and it does not replace therapy, support, careful follow-up or the work of rebuilding life around recovery.
Response varies. Some people notice relief sooner than they expected, some improve gradually and some do not improve enough to continue. You do not need to force hope into a guarantee. A steadier way to think about esketamine is this: it may reduce suffering enough to make other parts of healing more reachable, including therapy, relationships, sleep and daily routines.
Esketamine is not something to source on your own. It is not designed for at-home dosing and it does not promise that depressive symptoms will resolve. The clinic structure exists because supervision, observation and safety planning belong at the center of this treatment.
How SPRAVATO® Fits Into a Broader Care Plan
We see the most stability when medication decisions sit inside whole-person care, not on top of it. Esketamine can be one layer of treatment while you and your team keep working on the patterns, stressors and health factors that feed depression.
Supportive pieces that often matter alongside medication include:
None of these are meant to make recovery sound simple. They are part of a plan that gives your nervous system more support while your treatment team evaluates whether esketamine is helping.
How Esketamine Works: A Plain-Language Science Snapshot
Many antidepressants target serotonin, norepinephrine or dopamine more directly. Esketamine works differently by acting on the glutamate system, one of the brain’s main signaling pathways.
Glutamate affects how brain networks communicate, including circuits linked to mood, motivation and stress response. NMDA receptors are one part of that system. Esketamine affects NMDA activity and that change may influence how certain circuits connect and adapt.
Researchers are still mapping the full chain of events. Some people respond quickly, some respond over time and some do not respond enough to justify continuing. The science continues to develop, so your clinician can help you separate realistic expectations from online hype.
A Simple Way to Picture Glutamate and NMDA
You can picture glutamate as a set of signals that help brain cells “talk” to each other. NMDA works like one of the gates that shapes how those signals move. Esketamine changes how that gate behaves for a short period and that shift may affect how mood circuits fire and reconnect.
What “Downstream Effects” Means
“Downstream effects” means the brain rarely changes only one thing at a time. A change in glutamate signaling can ripple into other systems, including pathways involving norepinephrine and dopamine, in ways that may relate to mood and energy.
This helps explain why the experience may feel different from starting a daily pill. If you want a deeper overview, this peer-reviewed overview of esketamine walks through proposed mechanisms and open questions.
FDA Approval, Approved Uses and a Short History
Esketamine nasal spray was first approved by the FDA in 2019. Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson now marketed under Johnson & Johnson Innovative Medicine, manufactures the branded product SPRAVATO®.
Approved uses are specific and defined by labeling, including the requirement that treatment be administered in a certified setting. For treatment-resistant depression, esketamine may be used as a monotherapy or with an oral antidepressant. For major depressive disorder with acute suicidal ideation or behavior, it must be used with an oral antidepressant. Indications have expanded since the first approval and details can change as labeling updates.
When you want the most accurate wording, rely on the FDA-approved prescribing information. Your clinician can help you understand how the label applies to your diagnosis, risk factors and current medications.
From Research to 2019 Approval
Ketamine’s antidepressant effects were studied for years before an intranasal product was developed and tested in larger clinical trials. In 2019, the FDA approved esketamine nasal spray for a defined clinical use, with safety rules that require clinic administration and observation.
If primary sources help you feel more grounded, the label and updates give you the cleanest place to confirm what is indicated and what monitoring is required.
What the Evidence Shows, Without Hype
Esketamine research often measures change on depression rating scales, along with “response” or “remission” thresholds on those scales. Some studies also track relapse prevention, functioning and longer-term safety.
No single trial can answer every question for every patient. Trial populations may differ from real-world patients in comorbidities, trauma exposure, substance use history and the unevenness of everyday life. That does not weaken every finding. It does mean your expectations should stay personal, realistic and connected to your actual care plan.
When you read results, pause and ask a few grounded questions. Who was included? What was esketamine compared against? What else were participants taking? How long were they followed?
A Compact Evidence Snapshot
The TRANSFORM-2 trial studied adults with treatment-resistant depression and compared esketamine plus an oral antidepressant with placebo plus an oral antidepressant. Symptom change was measured over weeks.
The SUSTAIN-1 relapse prevention study used a randomized withdrawal design after people improved, then tracked relapse risk over time in a treatment-resistant depression population.
The SUSTAIN-2 long-term safety study followed participants receiving esketamine with an oral antidepressant and reported safety and tolerability outcomes across extended treatment.
The ASPIRE I trial evaluated esketamine in adults with major depressive disorder and acute suicidal ideation or behavior, measuring changes in depressive symptoms along with standard care.
Encouraging results can matter, but follow-up visits and ongoing support shape what happens after the first signs of relief.
What Research Cannot Tell You Yet
Research cannot predict your individual response with certainty. Your biology, medication history, trauma load, inflammation, pain conditions, sleep quality and support at home can all influence what happens.
Durability is personal too. Some people maintain gains with a structured plan. Others need schedule changes, more therapy support, medical reassessment or a different approach.
Mental health care often involves changing more than one variable. Medication, therapy, sleep timing, substance use and stress load can all shift the outcome, sometimes in uneven steps. That unevenness does not mean you are doing treatment wrong.
What to Expect With Supervised Dosing
Because esketamine is administered in a clinic, the treatment day has a clear structure. That structure is meant to protect you, not make care feel rigid.
Clinics may differ in small workflow details, but the basic sequence stays consistent because it is tied to safety requirements. Planning often lowers anxiety, especially before the first visit.
Before dosing, your care team will review medications, health history and recent symptoms. They may ask about alcohol or other substances, sleep and whether you have eaten. Transportation planning also matters because you cannot drive yourself home after treatment.
During dosing, you use the device in the clinic and remain on-site for observation. After dosing, most plans include a recovery period, a check on how you feel and guidance for the rest of the day.
During Your Esketamine Treatment Appointment
During your appointment, dosing happens in a clinical setting while staff monitor you. Many people sit in a comfortable chair, keep stimulation low and focus on moving through the window of effects with support nearby.
Some people notice dissociation, dizziness, nausea or a feeling of being “spaced out.” Others feel tired or emotionally tender. These sensations can feel unsettling when you do not know what to expect, so ask your clinic how they support comfort, grounding and reassurance during the visit.
After the observation period, you will be cleared to leave with a responsible ride. Many people plan a lighter schedule for the rest of the day because decision-making, coordination and focus can feel slower.
Safety, Side Effects and How Clinics Monitor
Side effects are part of why esketamine is given under observation. You can ask detailed questions about risks and you can take time before making decisions. Feeling cautious does not make you difficult. It means you are paying attention to your care.
Common adverse effects reported in labeling and trials include:
Monitoring exists because esketamine can temporarily affect blood pressure, alertness and perception. Staff often watch for changes in vital signs, distress, heavy sedation-like effects and whether you feel steady enough to leave safely.
Esketamine is subject to a Risk Evaluation and Mitigation Strategy, often called a REMS. You can read the FDA’s overview of Risk Evaluation and Mitigation Strategies to understand why some medications require extra safeguards.
Limitations, Contraindications and Extra-Caution Situations
Some situations call for extra caution. Your clinician may want tighter monitoring, added medical clearance or a different plan if you have uncontrolled blood pressure, certain cardiovascular conditions, a history of certain psychotic symptoms or active substance misuse.
Other situations may make treatment inappropriate, depending on your history and the current label. Pregnancy and breastfeeding questions, medication interactions and certain neurological risks should be handled directly with the prescriber.
The REMS program, in-clinic dosing and observation period are not optional add-ons. They form the framework that allows this treatment to be delivered in a controlled way.
Suicidal Thoughts: Please Read This With Care
If you are reading because you or someone you love feels suicidal, you are not alone and you should not have to carry that quietly. Many people ask whether esketamine can work “rapidly” and what that means when danger feels close.
In some studies, esketamine was associated with a faster reduction in depressive symptoms than placebo when used with standard care in a specific indicated population. That does not make it a stand-alone answer for imminent risk and it does not replace emergency support.
If safety is in question right now, treat the moment as urgent. Contact your clinician, call local emergency services or local crisis resources and involve a trusted person who can stay with you.
When to Seek Urgent Help
Seek urgent help if you feel at immediate risk of harming yourself, if you cannot commit to staying safe for the next few hours or if thoughts feel commanding or out of control. Call emergency services in your area or go to an emergency department.
If you can, reach out to someone you trust and say plainly what is happening. Many people also use international directories for crisis contacts, including local crisis resources listed by IASP.
Cognitive Effects, Daily Life and What Progress Can Look Like
Cognitive concerns are real. Many people worry about memory, focus or feeling “foggy,” especially when depression already makes thinking feel slow and heavy. Esketamine can cause short-term changes in perception and alertness on the day of dosing, which is one reason driving is restricted.
Longer-term cognitive outcomes are still being clarified. Clinical trials have included cognitive testing and published findings do not suggest broad, inevitable cognitive decline, but experiences vary and the evidence has limits. The safest reference point remains the FDA-approved prescribing information section on cognitive effects and precautions.
Daily life planning can make treatment feel less disruptive. Many people schedule treatment on a day with fewer work demands, avoid major decisions afterward and plan hydration and gentle meals that sit well. Your clinic may also ask you to avoid alcohol on treatment days.
Progress can look uneven. Some people notice mood shifting first. Others notice function first, like getting out of bed with less dread, replying to a text or cooking a meal. Side effects and logistics are part of progress too because tolerability determines whether a plan can hold over time.
How Clinicians Track Depressive Symptoms and Functioning
Clinicians often track depressive symptoms with rating scales, but they also look at life function. You may be asked about sleep continuity, appetite, motivation, anxiety, rumination and whether you are getting through basic tasks.
Function can be a clearer signal than mood in some weeks. Returning to a shower routine, working a partial day or re-engaging socially may count as meaningful movement, even if sadness is still present.
If your response is unclear, your team may reassess timing, dose schedule, your oral antidepressant, therapy supports and medical contributors like sleep apnea or thyroid issues. Reassessment belongs in good care. It does not mean you failed.
Cost, Access and Questions to Discuss With Your Clinician
Cost and access questions can create a second layer of stress when you are already worn down. Coverage can vary by plan, region and indication, and authorization processes can take time.
Practical factors that often affect access include visit frequency, the required monitoring window, transportation needs and time away from work or caregiving. Some people also need coordination between psychiatry and primary care if blood pressure or other medical issues are being managed.
At Memor Health, we often help patients coordinate medication treatment with therapy and lifestyle supports because logistics and recovery habits influence outcomes. That coordination can include scheduling therapy around treatment phases, establishing consistent sleep and creating a plan for at-home support after visits.
You can bring these questions to your clinician:
One whole-person question can also open a helpful conversation: “What else, besides medication, is most likely to raise my odds of recovery right now?”
That question can lead to sleep repair, movement, nutrition, relationship support and stress support without putting every ounce of pressure on one medication.
A Steady Way to Move Forward
Esketamine treatment can be a meaningful option for some people with treatment-resistant depression, especially when it sits inside a broader plan and is delivered with careful supervision. If you are considering it, bring your questions. Bring your fears too. A collaborative conversation gives you room to understand the treatment without feeling rushed into it.
You are not asking for too much by wanting relief and a plan that supports your whole life.
